TG Therapeutics, Inc. (TGTX) stock
TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$66.12+3.41 (+5.44%)
Close on Nov 18, 2026Market cap $10.12BP/E 24.1Yield –
TG Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
TG Therapeutics's price to sales ratio was 12.6× on Nov 11, 2026, against 9.7× a year earlier. Over the last 5 years it ranged from 7.6× to 493.1×, with a median of 14.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 12.6× | +3.9 |
| 2025 | Dec 31, 2025 | 8.7× | −9.0 |
| 2024 | Dec 31, 2024 | 17.7× | +4.1 |
| 2023 | Dec 29, 2023 | 13.6× | −328.6 |
| 2022 | Dec 30, 2022 | 342.2× | −150.9 |
| 2021 | Nov 30, 2021 | 493.1× | – |
See a number that looks wrong?